#1
Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines. Journal of Enzyme Inhibition and Medicinal Chemistry, 38(1), 2202358, 2023.
Link: https://doi.org/10.1080/14756366.2023.2202358
#2
Machine Learning-Based Approach to Developing Potent EGFR Inhibitors for Breast Cancer─ Design, Synthesis, and In Vitro Evaluation. ACS omega, 2023
Link: https://doi.org/10.1021/acsomega.3c02799